Location
-
In this table, GlobalCapital Asia offers a glimpse of the bond deals that are in the works -
The market is predicted to reach an all-time high for new issue volumes in 2022
-
Chinese biopharma firm parks over 70% of the IPO with cornerstones
-
The firm priced its share at HK$158, with the top 15 investors taking around 70% of the offer
-
The dollar project funding is among the largest in India in the renewable energy sector
-
-
In this table, GlobalCapital Asia offers a glimpse of the bond deals that are in the works
-
Smaller, privately owned companies are becoming a key part of the local IPO market
-
Despite better markets, few expect issuance volumes to recover from lowest levels in years
-
Short maturities and double digit concessions gloss over impending gas crisis in Europe
-
Long and short deals from MuHyp and Sparebank 1 had smoother execution
-
Almost all corporate bonds held by Bank eligible for its auction process with buy-backs also on offer
